CYP19A1 and breast cancer: Other models have been used to assess how impactful sex hormones are on bone health, such as cisgender men with aromatase gene deficiency or cisgender women taking aromatase inhibitors for breast cancer; the evidence derived from these subgroups further support the pivotal role that circulating estrogens play in promoting bone health [40, 41].